Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Pediatric Formulations of Triumeq and Dovato
NCT04827134Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir and dolutegravir + lamivudine in human immunodeficiency virus infection (HIV) (4 cohorts), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity, Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Observed Quantifiable Concentration and 1 more. Started May 2021; status: completed.
02
Drugs
dolutegravirdolutegravir + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04827134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827134.